Contrasting Proteon Therapeutics (PRTO) and Its Rivals
Proteon Therapeutics (NASDAQ: PRTO) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Proteon Therapeutics to related businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings.
This table compares Proteon Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Proteon Therapeutics Competitors||-9,545.89%||-430.95%||-40.60%|
Earnings & Valuation
This table compares Proteon Therapeutics and its peers revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Proteon Therapeutics||$2.95 million||-$28.52 million||-0.81|
|Proteon Therapeutics Competitors||$286.20 million||$34.74 million||136.41|
Proteon Therapeutics’ peers have higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings for Proteon Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Proteon Therapeutics Competitors||805||3166||11480||230||2.71|
Proteon Therapeutics presently has a consensus price target of $6.86, indicating a potential upside of 281.11%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.95%. Given Proteon Therapeutics’ higher probable upside, analysts plainly believe Proteon Therapeutics is more favorable than its peers.
Institutional & Insider Ownership
50.3% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 49.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 36.3% of Proteon Therapeutics shares are held by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Proteon Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Proteon Therapeutics’ peers have a beta of 1.47, indicating that their average share price is 47% more volatile than the S&P 500.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.